Autoimmune liver disease (AILD) is a type of chronic liver disease with autoimmune etiology. The diagnosis of the disease is multipronged and detection of autoantibodies in AILDs is an important diagnostic tool and it also helps in the classification of the disease. There are multiple autoantibodies that are detected in AILDs but none is diagnostic. Moreover, these autoantibodies are detected in many other pathological and nonpathological conditions. So the significance of seropositivity for these autoantibodies should be known by both the pathologists as well as the clinicians. In addition, there is prognostic significance associated with some of the antibodies and they also sometimes help in the disease monitoring. The whole array of antibodies detected in AILDs is discussed in detail in this review along with their clinical significance and interpretation.
BeuersUGershwinMEGishRG. Changing nomenclature for PBC: from “cirrhosis” to “cholangitis”. Am J Gastroenterol. 2015;110:1536-1538.
8.
AlvarezFBergPABianchiFB. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938.
9.
HennesEMZeniyaMCzajaAJ. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169-176.
10.
BogdanosDPInvernizziPMackayIRVerganiD. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol. 2008;14:3374-3387.
TerjungBWormanHJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15:629-642.
15.
Mieli-VerganiGVerganiD. Autoimmune hepatitis in children: what is different from adult AIH?Semin Liver Dis. 2009;29:297-306.
16.
ChazouilleresOWendumDSerfatyLMontembaultSRosmorducOPouponR. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296-301.
17.
PouponRChazouilleresOCorpechotCChretienY. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44:85-90.
18.
MinzRWChhabraSAggarwalRDasASaikiaBChawlaYK. Incipient primary biliary cirrhosis/autoimmune hepatitis overlap or hepatitic form of primary biliary cirrhosis: a case report. Cases J. 2009;2:7491.
StrassburgCPAlexBZindyF. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J Hepatol. 1996;25:859-866.
21.
StrassburgCPMannsMP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis. 2002;22:339-352.
CzajaAJHomburgerHA. Autoantibodies in liver disease. Gastroenterology. 2001;120:239-249.
24.
CzajaAJMorshedSAParveenSNishiokaM. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology. 1997;26:567-572.
25.
DalekosGNZachouKLiaskosCGatselisN. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med. 2002;13:293-303.
26.
ZachouKRigopoulouEDalekosGN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis. 2004;1:2.
27.
CzajaAJCassaniFCataletaMValentiniPBianchiFB. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci. 1997;42:1688-1696.
28.
CzajaAJMannsMP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol. 1995;90:1206-1211.
29.
StrassburgCPMannsMP. Antinuclear antibody (ANA) patterns in hepatic and extrahepatic autoimmune disease. J Hepatol. 1999;31:751.
30.
CourvalinJCWormanHJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis. 1997;17:79-90.
31.
SzosteckiCGuldnerHHWillH. Autoantibodies against “nuclear dots” in primary biliary cirrhosis. Semin Liver Dis. 1997;17:71-78.
TerjungBSpenglerU. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol. 2005;28:115-133.
34.
KaplanMMGershwinME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261-1273.
35.
RigopoulouEIDaviesETParesA. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005;54:528-532.
36.
MuratoriLDeleonardiGLalanneC. Autoantibodies in autoimmune hepatitis. Dig Dis. 2015;33(suppl 2):65-69.
37.
SenerAG. Autoantibodies in autoimmune liver diseases. APMIS. 2015;123:915-919.
38.
BogdanosDPMieli-VerganiGVerganiD. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis. 2009;29:241-253.
39.
CzajaAJCassaniFCataletaMValentiniPBianchiFB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996;24:1068-1073.
40.
BottazzoGFFlorin-ChristensenAFairfaxASwanaGDoniachDGroeschel-StewartU. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol. 1976;29:403-410.
41.
WhittinghamSIrwinJMackayIRSmalleyM. Smooth muscle autoantibody in “autoimmune” hepatitis. Gastroenterology. 1966;51:499-505.
42.
GatselisNKGeorgiadouSPKoukoulisGK. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther. 2006;24:1563-1573.
43.
GranitoAMuratoriLMuratoriP. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol. 2006;59:280-284.
44.
GranitoAMuratoriPMuratoriLGeorgiosPLenziMBianchiFB. Antifilamentous actin antibodies by ELISA for the diagnosis of type 1 autoimmune hepatitis. Am J Gastroenterol. 2007;102:1131-1132.
45.
VillaltaDBizzaroNDa ReMTozzoliRKomorowskiLTonuttiE. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders. Autoimmunity. 2008;41:105-110.
46.
TohBH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol. 1979;38:621-628.
47.
GregorioGVMcFarlaneBBrackenPVerganiDMieli-VerganiG. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity. 2002;35:515-519.
48.
VolkmannMMartinLBaurleA. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology. 2001;33:591-596.
49.
GelpiCSontheimerEJRodriguez-SanchezJL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A. 1992;89:9739-9743.
50.
BallotEHombergJCJohanetC. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol. 2000;33:208-215.
51.
YamamotoAMCresteilDHombergJCAlvarezF. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology. 1993;104:1762-1767.
52.
GueguenMYamamotoAMBernardOAlvarezF. Anti-liver-kidney microsome antibody type 1 recognizes human cytochrome P450 db1. Biochem Biophys Res Commun. 1989;159:542-547.
53.
HombergJCAbuafNBernardO. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology. 1987;7:1333-1339.
54.
MannsMPJohnsonEFGriffinKJTanEMSullivanKF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest. 1989;83:1066-1072.
55.
ZangerUMHauriHPLoeperJHombergJCMeyerUA. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci U S A. 1988;85:8256-8260.
56.
MiyakawaHKitazawaEKikuchiK. Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C. Autoimmunity. 2000;33:23-32.
57.
WuCHXuXYTianGSYuYY. Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus [in Chinese]. Zhonghua Yi Xue Za Zhi. 2006;86:390-393.
58.
JohnsonPJMcFarlaneIG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998-1005.
59.
JadaliZAlavianSM. Autoimmune diseases co-existing with hepatitis C virus infection. Iran J Allergy Asthma Immunol. 2010;9:191-206.
60.
LunelFAbuafNFrangeulL. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology. 1992;16:630-636.
61.
BeaunePDansettePMMansuyD. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A. 1987;84:551-555.
62.
PhilippTDurazzoMTrautweinC. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet. 1994;344:578-581.
63.
CrivelliOLavariniCChiabergeE. Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin Exp Immunol. 1983;54:232-238.
64.
CsepregiANemesanszkyELuettigBObermayer-StraubPMannsMP. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol. 2001;96:910-911.
65.
DavisPALeungPMannsM. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena?Hepatology. 1992;16:1128-1136.
66.
BergPAKleinRLindenborn-FotinosJKloppelW. ATPase-associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis. Lancet. 1982;2:1423-1426.
67.
BraunSBergCBuckSGregorMKleinR. Catalytic domain of PDC-E2 contains epitopes recognized by antimitochondrial antibodies in primary biliary cirrhosis. World J Gastroenterol. 2010;16:973-981.
68.
MackayIRWhittinghamSFidaS. The peculiar autoimmunity of primary biliary cirrhosis. Immunol Rev. 2000;174:226-237.
69.
YeamanSJ. The 2-oxo acid dehydrogenase complexes: recent advances. Biochem J. 1989;257:625-632.
70.
ButlerPHamilton-MillerJBaumHBurroughsAK. Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis?Biochem Mol Biol Int. 1995;35:473-485.
71.
KleinRWiebelMEngelhartSBergPA. Sera from patients with tuberculosis recognize the M2a-epitope (E2-subunit of pyruvate dehydrogenase) specific for primary biliary cirrhosis. Clin Exp Immunol. 1993;92:308-316.
LapierrePHajouiOHombergJCAlvarezF. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116:643-649.
74.
AbuafNJohanetCChretienP. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology. 1992;16:892-898.
75.
MartiniEAbuafNCavalliFDurandVJohanetCHombergJC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology. 1988;8:1662-1666.
76.
LankischTOJaeckelEStrassburgCP. The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy or autoimmune polyglandular syndrome type 1. Semin Liver Dis. 2009;29:307-314.
77.
ClementeMGObermayer-StraubPMeloniA. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 1997;82:1353-1361.
78.
Gebre-MedhinGHusebyeESGustafssonJ. Cytochrome P450IA2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I. FEBS Lett. 1997;412:439-445.
79.
Obermayer-StraubPPerheentupaJBraunS. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology. 2001;121:668-677.
80.
TreichelUMcFarlaneBMSekiT. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology. 1994;107:799-804.
81.
FalkRJJennetteJC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988;318:1651-1657.
82.
DuerrRHTarganSRLandersCJ. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1991;100:1385-1391.
83.
TerjungBWormanHJHerzogVSauerbruchTSpenglerU. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol. 2001;126:37-46.
RoozendaalCde JongMAvan den BergAPvan WijkRTLimburgPCKallenbergCG. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol. 2000;32:734-741.
86.
TerjungBHerzogVWormanHJ. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology. 1998;28:332-340.
87.
SavigeJDimechWFritzlerM. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol. 2003;120:312-318.
88.
CzajaAJFreeseDK; American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479-497.
